
## **Caroline F Samer**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1522444/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Applications of CYP450 Testing in the Clinical Setting. Molecular Diagnosis and Therapy, 2013, 17, 165-184.	3.8	296
2	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
3	Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2017, 28, 2241-2248.	6.1	171
4	Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British Journal of Pharmacology, 2010, 160, 919-930.	5.4	156
5	The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology, 2010, 160, 907-918.	5.4	141
6	Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?. Hepatology, 2013, 57, 2180-2188.	7.3	136
7	Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots. Clinical Pharmacology and Therapeutics, 2014, 96, 349-359.	4.7	112
8	Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 251-260.	7.7	98
9	Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics, 2008, 9, 905-933.	1.3	91
10	Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 359-367.	2.8	73
11	Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. European Journal of Internal Medicine, 2015, 26, 399-406.	2.2	59
12	Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ, The, 2021, 374, n2040.	6.0	54
13	Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. Clinical Pharmacokinetics, 2018, 57, 1347-1354.	3.5	52
14	Human urinary biomarkers of dioxin exposure: Analysis by metabolomics and biologically driven data dimensionality reduction. Toxicology Letters, 2014, 230, 234-243.	0.8	51
15	Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability. Current Drug Metabolism, 2010, 11, 667-677.	1.2	49
16	Simultaneous LC–MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis, 2014, 6, 151-164.	1.5	46
17	Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Frontiers in Pharmacology, 2016, 7, 494.	3.5	45
18	Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 132-137.	2.5	43

CAROLINE F SAMER

#	Article	IF	CITATIONS
19	Evaluation of Mutual Drug–Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 284-290.	2.5	43
20	Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clinical Pharmacology and Therapeutics, 2021, 109, 1668-1676.	4.7	42
21	HIV-Positive-to-HIV-Positive Liver Transplantation. American Journal of Transplantation, 2016, 16, 2473-2478.	4.7	40
22	Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review. Current Drug Metabolism, 2014, 15, 326-343.	1.2	39
23	Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clinical Pharmacology and Therapeutics, 2016, 100, 295-304.	4.7	36
24	Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. Clinical Pharmacokinetics, 2018, 57, 1267-1293.	3.5	36
25	Impact of SARSâ€CoVâ€2 Infection (COVIDâ€19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clinical Pharmacology and Therapeutics, 2021, 110, 1358-1367.	4.7	36
26	Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature. Frontiers in Pharmacology, 2021, 12, 733935.	3.5	36
27	When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. Frontiers in Pharmacology, 2018, 9, 148.	3.5	34
28	PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients. BMJ Open, 2017, 7, e016070.	1.9	30
29	Oral Flurbiprofen Metabolic Ratio Assessment Using a Single-Point Dried Blood Spot. Clinical Pharmacology and Therapeutics, 2012, 91, 489-496.	4.7	27
30	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics Journal, 2019, 19, 211-218.	2.0	25
31	Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends. Frontiers in Pharmacology, 2021, 12, 708299.	3.5	24
32	Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. Clinical Pharmacokinetics, 2014, 53, 261-269.	3.5	23
33	Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 129-137.	2.8	23
34	Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacology Research and Perspectives, 2020, 8, e00647.	2.4	21
35	Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. Swiss Medical Weekly, 2020, 150, w20446.	1.6	21
36	Serotonin syndrome following drug–drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. Aids, 2012, 26, 2417-2418.	2.2	20

#	Article	IF	CITATIONS
37	Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-8.	2.5	16
38	Prevention of potentially inappropriate medication in internal medicine patients: A prospective study using the electronic application PIM-Check. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 860-866.	1.5	14
39	Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS Research and Therapy, 2014, 11, 25.	1.7	13
40	Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacological Research, 2017, 118, 104-110.	7.1	13
41	Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling. Pediatric Research, 2020, 87, 441-449.	2.3	13
42	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. American Journal of Medicine, 2021, 134, 939-942.	1.5	13
43	Direct oral anticoagulants: efficacy and safety in patient subgroups. Swiss Medical Weekly, 2015, 145, w14081.	1.6	13
44	Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 659-669.	3.3	12
45	The European Association for Clinical Pharmacology and Therapeutics—25Âyears' young and going strong. European Journal of Clinical Pharmacology, 2019, 75, 743-750.	1.9	11
46	Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review. Clinical Pharmacokinetics, 2021, 60, 1537-1555.	3.5	11
47	Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. Personalized Medicine, 2006, 3, 239-269.	1.5	10
48	Carbimazole-Induced, ANCA-Associated, Crescentic Glomerulonephritis: Case Report and Literature Review. Renal Failure, 2013, 35, 414-417.	2.1	10
49	Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study. Journal of Personalized Medicine, 2020, 10, 198.	2.5	10
50	CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting. Frontiers in Pharmacology, 2021, 12, 730637.	3.5	10
51	Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir. Aids, 2013, 27, 2827-2828.	2.2	9
52	Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. Journal of Personalized Medicine, 2021, 11, 250.	2.5	9
53	Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 1123-1131.	1.9	8
54	Safety Issues of Pharmacological Acute Pain Treatment in Children. Clinical Pharmacology and Therapeutics, 2019, 105, 1130-1138.	4.7	7

#	Article	IF	CITATIONS
55	Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 30-43.	2.5	7
56	Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail. Journal of Personalized Medicine, 2019, 9, 45.	2.5	6
57	Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. European Journal of Hospital Pharmacy, 2023, 30, 113-116.	1.1	6
58	Dexamethasone exposure in normalâ€weight and obese hospitalized <scp>COVID</scp> â€19 patients: An observational exploratory trial. Clinical and Translational Science, 2022, 15, 1796-1804.	3.1	6
59	Case Report: Low Hematocrit Leading to Tacrolimus Toxicity. Frontiers in Pharmacology, 2021, 12, 717148.	3.5	5
60	Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review. Current Drug Metabolism, 2015, 16, 97-104.	1.2	5
61	PIII-1Determinant role of CYP2D6 and CYP3A4 pathways on the antinociceptive effects of oxycodone. Clinical Pharmacology and Therapeutics, 2006, 79, P57-P57.	4.7	4
62	Individualizing analgesic prescription. Part II: pharmacogenetics of anti-inflammatory analgesics and co-analgesics. Personalized Medicine, 2006, 3, 271-297.	1.5	4
63	Influence des polymorphismes génétiques sur la variabilité de la réponse aux opioÃ⁻des. Douleur Et Analgesie, 2013, 26, 203-208.	0.1	4
64	Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. AÂcase report and review. New Microbes and New Infections, 2015, 6, 1-4.	1.6	4
65	Preclinical Evaluation of Safety of Fucoidan Extracts From <i>Undaria pinnatifida</i> and <i>Fucus vesiculosus</i> for Use in Cancer Treatment. Integrative Cancer Therapies, 2019, 18, 153473541987632.	2.0	4
66	Cyber harassment of female scientists will not be the new norm. Lancet Infectious Diseases, The, 2021, 21, 457-458.	9.1	4
67	Development and Preliminary Validation of LoAD Calc, a Mobile App for Calculating the Maximum Safe Single Dose of Local Anesthetics. Healthcare (Switzerland), 2021, 9, 799.	2.0	4
68	Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit–risk assessment for natalizumab. Journal of Travel Medicine, 2021, 28, .	3.0	4
69	Hydromorphone Prescription for Pain in Children—What Place in Clinical Practice?. Frontiers in Pediatrics, 2022, 10, 842454.	1.9	4
70	Cytochrome P450 1A2 activity and incidence of thyroid disease and cancer after chronic or acute exposure to dioxins. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 296-303.	2.5	3
71	The Swiss Cheese Prescribing Model for Precision Medicine. American Journal of Medicine, 2020, 133, 1249-1251.	1.5	3
72	Mixing Drugs and Genetics: A Complex Hemorrhagic Cocktail. American Journal of Medicine, 2021, 134, e211-e212.	1.5	3

CAROLINE F SAMER

#	Article	IF	CITATIONS
73	Automatic Classification of Discharge Letters to Detect Adverse Drug Reactions. Studies in Health Technology and Informatics, 2020, 270, 48-52.	0.3	3
74	Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation― Circulation, 2016, 134, e3-4.	1.6	2
75	"Late―Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn. Frontiers in Pharmacology, 2017, 8, 217.	3.5	2
76	Severe and persistent morphine-induced respiratory depression associated with ATP-Binding Cassette Subfamily B Member 1 and catechol-O-methyltransferase genetic defects. European Journal of Anaesthesiology, 2018, 35, 540-542.	1.7	2
77	Vitamin D and Glaucoma: A Critical Review of the Literature. Journal of Ophthalmology, 2020, 2020, 1-8.	1.3	2
78	Clinical Course and Management of latrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic Review. Journal of Antivirals & Antiretrovirals, 2013, 05, .	0.1	2
79	Pharmacogénétique des anti-inflammatoires non stéroÃ <sup>-</sup> diens. Douleur Et Analgesie, 2013, 26, 195-202.	0.1	1
80	Providing Quality Therapeutics in Switzerland: Role of the Stakeholders and Recent Incentives for Further Improvements. Clinical Therapeutics, 2015, 37, 1588-1592.	2.5	1
81	Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). Drug Metabolism and Personalized Therapy, 2017, 32, 173-174.	0.6	1
82	Absorption des médicaments lors de syndrome du grêle court. Nutrition Clinique Et Metabolisme, 2018, 32, 143-149.	0.5	1
83	Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs. Frontiers in Pharmacology, 2021, 12, 834717.	3.5	1
84	Analgésie, l'importance du polymorphisme génétique du cytochrome P450 2D6 dans l'individualis thérapeutique. Douleur Et Analgesie, 2004, 17, 63-66.	ation 0.1	0
85	How close are we to individual analgesic adjustment according to a patient's genotype?. Personalized Medicine, 2011, 8, 289-292.	1.5	0
86	In-vitro evaluation of DDI with cobicistat and ritonavir using heparg cell line. Clinical Therapeutics, 2015, 37, e98.	2.5	0
87	Screening for phenotypical variation in CYP activity in patients with therapeutic problem in psychiatric settings. Clinical Therapeutics, 2015, 37, e41-e42.	2.5	0
88	Evaluation of CYP450 and transporters expression and activity in heparg cell line under different conditions. Clinical Therapeutics, 2015, 37, e98.	2.5	0
89	Innovative approach to Blood sampling using dried Blood spots. application to Pharmacokinetics and Cytochrome P450 Phenotyping. Clinical Therapeutics, 2015, 37, e101.	2.5	0
90	Formation des médecins et infirmières à l'utilisation des opiacés par un jeu sérieux. Douleur Et Analgesie, 2019, 32, 54-60.	0.1	0

CAROLINE F SAMER

#	Article	IF	CITATIONS
91	Development and validation of LoAD Calc, a mobile app for calculating the maximum safe single dose of local anesthetics (Preprint). JMIR Formative Research, 0, , .	1.4	0
92	Prescription de tramadol chez les enfants : une bonne alternative à la codéine ?. Douleur Et Analgesie, 2020, 33, 247-256.	0.1	0
93	Citizens' Participation in Health and Scientific Research in Switzerland. Studies in Health Technology and Informatics, 2020, 270, 1098-1102.	0.3	0